<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121205">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02149771</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-IR 2013</org_study_id>
    <nct_id>NCT02149771</nct_id>
  </id_info>
  <brief_title>Combination Treatment for Advanced Liver Cancer</brief_title>
  <official_title>Transarterial Chemoembolisation (TACE) Combined With Endovascular Implantation of Bare Stent and Iodine-125 Seed Strand for the Treatment of Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis Versus TACE Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai Municipal Science and Technology Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <authority>China: ZhongShan hospital Fudan Uinivercity</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether TACE combined endovascular stent
      implantation confers a survival benefit over TACE alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Median survival time</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Hepatic Portal Vein Tumor Invasion</condition>
  <arm_group>
    <arm_group_label>TACE&amp;Stents</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chemoembolization combined with endovascular stents and iodine-125 seed strand implantation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TACE</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transartery chemoembolisation（TACE） by administering Doxorubicin and Oxaliplatin mixed with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>chemoembolization</intervention_name>
    <description>Conventional chemoembolisation by administering Doxorubicin and Oxaliplatin mix with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.</description>
    <arm_group_label>TACE&amp;Stents</arm_group_label>
    <arm_group_label>TACE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>endovascular stents implantation</intervention_name>
    <description>Bare stents implant within portal vein.</description>
    <arm_group_label>TACE&amp;Stents</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>iodine-125 seed strand implantation</intervention_name>
    <description>Iodine-125 seed strand implant within portal vein.</description>
    <arm_group_label>TACE&amp;Stents</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  (1) Hepatocellular carcinoma(HCC) diagnosis confirmed by needle biopsy or by two
             coincidental imaging techniques associated with increased α-fetoprotein according to
             the American Association for the Study of Liver Diseases (AASLD) guidelines and
             contrast-enhancing tumour thrombus within the main portal vein and one of the
             first-order branch on CT or MRI;

          -  (2) Child-Pugh classification grade A or B；

          -  （3）Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less.

        Exclusion Criteria:

          -  advanced liver disease (bilirubin levels &gt;3 mg/dL, ASTor ALT &gt;5 × upper limit of
             normal)；

          -  Tumor invade the Inferior Vena Cava, extrahepatic spread;

          -  contraindications for doxorubicin or oxaliplatin chemotherapy;

          -  any contraindication to an arterial procedure such as impaired clotting tests
             (platelet count below 50 × 109/L or prothrombin activity below 50 %);

          -  renal failure,cardiac ejection fraction &lt;50 %) or end-stage disease；

          -  patients who were not capable of cooperation during the procedure.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhinping Yan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Interventional Radiology, Zhongshan Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jianjun Luo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Interventional Radiology, Zhongshan Hospital, Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minjie Yang, MD</last_name>
    <phone>+8613818947653</phone>
    <email>522623124@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qinghui Yang, MD</last_name>
    <phone>+8613917628732</phone>
    <email>yangminjie123@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Interventional Radiology, Zhongshan Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianjun Luo, MD</last_name>
      <email>522623124@qq.com</email>
    </contact>
    <investigator>
      <last_name>Zhinping Yan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jianjun Luo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>May 25, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Zhiping Yan</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>portal vein tumor thrombosis</keyword>
  <keyword>stents</keyword>
  <keyword>chemoembolization</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
